The creation of legacies is an essential aspect of coping and meaning-making. Our webinars discuss legacy-making across the lifespan. Ranging from creative perspectives via art, music, and writing to hearing personal stories from family members with lived experiences, we will learn about the process, importance and integration of legacy-making. Please join us and our wonderful speakers to learn about legacy-making through a multicultural and global perspective.
As part of our ongoing efforts to provide our members with the latest information sharing tools and forums for discussion, we are pleased to offer recorded webcasts. These are open to members and non-members, with members having access for free or at a special discounted rate.
Presenters volunteer their time and expertise when hosting webinars and we encourage viewers to donate to IPOS so we can continue to provide our webinars complimentary to members and at a minimum cost for non-members.
Not a current member of IPOS? Find out more by going to https://ipos.wildapricot.org/membership/apply
Available 2024 Webcasts:
Self-management in cancer survivorship (Part-II) (recorded December 9, 2022)
Self-management in cancer survivorship (Part-I) (recorded July 22, 2022)
Developing Psycho-oncology in LMICs” – Part 1 (Africa, S. America, India) (recorded May 25, 2022)
Fear of Recurrence: The Experience of Caregivers (recorded March 31, 2022)
COVID’s Global Impact on Palliative Care: Creating Connections (recorded October 21, 2021)
IPOS Survivorship Group Presents: Managing sleep difficulties in cancer (recorded April 29, 2021)
Cancer in the Elderly / Personas Mayores CON Cancer (recorded December 2020)
A burden shared: group-based interventions for fear of cancer recurrence (recorded December 8, 2020)
The Social Context of Fear of Cancer Recurrence (recorded September 22, 2020)
Impact of the COVID-19 Pandemic on Cancer Care (recorded June 2020)
Grupos de auto-ayuda como apoyo psicosocial para mujeres latinas con cáncer (recorded June 24, 2020)
Applying ACT strategies to a cancer population within the context of COVID -19